Literature DB >> 1303853

Transpupillary thermotherapy (TTT) by infrared irradiation of choroidal melanoma.

J G Journée-de Korver1, J A Oosterhuis, H M Kakebeeke-Kemme, D de Wolff-Rouendaal.   

Abstract

We studied the destructive effect of hyperthermia at sub-photocoagulation level of 45-60 degrees C on melanomas. Optimal conditions for spreading of heat into tissue are a wavelength of 700-900 nm, a temperature of 45-60 degrees C, an exposure time of 1 minute or more, and a beam diameter of several millimeters. In hamsters with subcutaneous melanomas we obtained a tumour necrosis of 6 mm depth at 60 degrees C and one minute exposure time. We performed transpupillary thermotherapy (TTT) with a diode laser at 810 nm in patients with choroidal melanomas prior to enucleation. Treatment is based on the fortunate situation that irradiation at this wavelength combines optimal tissue penetration with a low absorption by clear ocular media of 5% or less. In 3 TTT-treated eyes histopathology showed a depth of necrosis of 0.9, 3.4, and 3.9 mm. TTT may become a new useful treatment modality for choroidal melanoma but its ultimate value has yet to be assessed.

Entities:  

Mesh:

Year:  1992        PMID: 1303853     DOI: 10.1007/bf00160764

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  13 in total

1.  Tumor destruction by intermediate level hyperthermia.

Authors:  E M Nuijs-Beems; J A Oosterhuis; E H Verburg-van der Marel; D de Wolff-Rouendaal; J L van Delft; J A van Best
Journal:  Curr Eye Res       Date:  1990-08       Impact factor: 2.424

2.  Heat-induced damage to HeLa-S3 cells: correlation of viability, permeability, osmosensitivity, phase-contrast light-, scanning electron- and transmission electron-microscopical findings.

Authors:  D N Wheatley; C Kerr; D W Gregory
Journal:  Int J Hyperthermia       Date:  1989 Mar-Apr       Impact factor: 3.914

3.  Ocular spectral characteristics as related to hazards from lasers and other light sources.

Authors:  W J Geeraets; E R Berry
Journal:  Am J Ophthalmol       Date:  1968-07       Impact factor: 5.258

4.  Thermoradiotherapy of choroidal melanoma. Clinical experience.

Authors:  P T Finger; S Packer; R W Paglione; J F Gatz; T K Ho; J L Bosworth
Journal:  Ophthalmology       Date:  1989-09       Impact factor: 12.079

Review 5.  [Hyperthermic therapy procedures for supplementing radiotherapy of malignant intraocular tumors].

Authors:  K G Riedel
Journal:  Klin Monbl Augenheilkd       Date:  1988-08       Impact factor: 0.700

6.  Thermal and optical properties of living tissue: application to laser-induced hyperthermia.

Authors:  L O Svaasand; T Boerslid; M Oeveraasen
Journal:  Lasers Surg Med       Date:  1985       Impact factor: 4.025

Review 7.  Xenon arch photocoagulator used for transpupillary hyperthermia.

Authors:  J G Journée-de Korver; J A Oosterhuis; J A van Best; J Fakkel
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

8.  Hematoporphyrin derivative photoradiation treatment of experimental malignant melanoma in the anterior chamber of the rabbit.

Authors:  K A Franken; J L van Delft; T M Dubbelman; D de Wolff-Rouendaal; J A Oosterhuis; W M Star; H P Marijnissen
Journal:  Curr Eye Res       Date:  1985-05       Impact factor: 2.424

9.  Low-energy long-exposure laser therapy in the management of choroidal melanoma.

Authors:  W S Foulds; B E Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

10.  Infrared contact coagulation: a new approach for local hyperthermic therapy of solid animal tumors.

Authors:  C Lersch; C Hammer; O Ganghoff; J Meyer; W Brendel; F Krombach; G Nath
Journal:  Oncology       Date:  1984       Impact factor: 2.935

View more
  13 in total

1.  Yellow dye laser thermotherapy of choroidal neovascularisation in age related macular degeneration.

Authors:  M R Beintema; J A Oosterhuis; F Hendrikse
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Eye imaging with a 3.0-T MRI using a surface coil--a study on volunteers and initial patients with uveal melanoma.

Authors:  Arne-Jörn Lemke; Minouche Alai-Omid; Susanne Anja Hengst; Iris Kazi; Roland Felix
Journal:  Eur Radiol       Date:  2006-01-06       Impact factor: 5.315

Review 3.  [Capillary hemangioma of the retina in cases of von Hippel-Lindau syndrome. New therapeutic directions].

Authors:  N Bornfeld; K-M Kreusel
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications.

Authors:  Klaus-Martin Kreusel; Nikolaos Bechrakis; Juliane Riese; Lothar Krause; Joachim Wachtlin; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

5.  Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

Authors:  H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1998

6.  Primary transpupillary thermotherapy for small choroidal melanoma.

Authors:  Martha Motono Chojniak; Rubens Chojniak; Ines Nobuko Nishimoto; Norma Allemann; Clélia Maria Erwenne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-06-29       Impact factor: 3.117

Review 7.  Animal Eye Models for Uveal Melanoma.

Authors:  Jinfeng Cao; Martine J Jager
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

8.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

9.  [Transpupillary thermotherapy (TTT) for uveal melanomas. Long term results of a single TTT with an adapter for a conventional infrared laser].

Authors:  G Langmann; H Lechner; E Wenzel; G Mossböck; W Wackernagel
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

10.  Bevacizumab and intraocular tumors: an intriguing paradox.

Authors:  Mariam el Filali; Long V Ly; Gregorius P M Luyten; Mieke Versluis; Hans E Grossniklaus; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2012-10-05       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.